Advanced in Ewing Sarcoma

Dr. Elizabeth A. Sokol

Pediatric Hematology Oncology
Lurie Children's Medical Group Inc.
225 E Chicago Ave, 
Chicago, IL 
Advanced in Ewing Sarcoma
Lurie Children's Medical Group Inc.
225 E Chicago Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Sokol is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Sokol is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Febrile Neutropenia, and Hereditary Neuroblastoma.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Ewing Sarcoma.

Graduate Institution
University Of Illinois College Of Med (Chi/peor/rock/chm-Urb)
Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

LURIE CHILDREN'S MEDICAL GROUP INC.
225 E Chicago Ave, Chicago, IL 60611

Additional Areas of Focus

Dr. Sokol has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: Elimusertib
Study Phase: Phase 1/Phase 2
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Phase: Phase 1
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2024
Intervention Type: Other
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Irinotecan, Pevonedistat, Temozolomide
Study Phase: Phase 1
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2024
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide
Study Phase: Phase 2
View 8 Less Clinical Trials

22 Total Publications

Large-Bore Vacuum Suction Biopsy of Pediatric Soft Tissue Tumors: A 5-Year Retrospective Analysis of Safety and Effectiveness.
Large-Bore Vacuum Suction Biopsy of Pediatric Soft Tissue Tumors: A 5-Year Retrospective Analysis of Safety and Effectiveness.
Journal: Pediatric blood & cancer
Published: June 22, 2025
Similar Doctors
Distinguished in Ewing Sarcoma
Dr. David O. Walterhouse
Pediatric Hematology Oncology
Distinguished in Ewing Sarcoma
Dr. David O. Walterhouse
Pediatric Hematology Oncology
2300 Childrens Plaza, Division Of Hematology/oncology Box 30, 
Chicago, IL 
 (2.4 miles away)
773-755-6514
Languages Spoken:
English
See accepted insurances

David Walterhouse is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Walterhouse is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, and Bone Marrow Aspiration.

Advanced in Ewing Sarcoma
Dr. Jennifer L. Reichek
Pediatric Hematology Oncology
Advanced in Ewing Sarcoma
Dr. Jennifer L. Reichek
Pediatric Hematology Oncology

Lurie Children's Medical Group Inc.

225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-6415
Languages Spoken:
English
See accepted insurances

Jennifer Reichek is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Reichek is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Neuroblastoma, Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), and Osteosarcoma.

Advanced in Ewing Sarcoma
Dr. Amy L. Walz
Pediatric Hematology Oncology
Advanced in Ewing Sarcoma
Dr. Amy L. Walz
Pediatric Hematology Oncology

Lurie Children's Medical Group Inc.

225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-6415
Languages Spoken:
English
See accepted insurances

Amy Walz is a Pediatric Hematologist Oncology provider in Chicago, Illinois. Dr. Walz is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Ewing Sarcoma, Hereditary Neuroblastoma, Neuroblastoma, and Acute Lymphoblastic Leukemia (ALL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sokol's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile